Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

178 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
Pastor F, Kolonias D, McNamara JO 2nd, Gilboa E. Pastor F, et al. Among authors: gilboa e. Mol Ther. 2011 Oct;19(10):1878-86. doi: 10.1038/mt.2011.145. Epub 2011 Aug 9. Mol Ther. 2011. PMID: 21829171 Free PMC article.
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E. Schrand B, et al. Among authors: gilboa e. Cancer Immunol Res. 2014 Sep;2(9):867-77. doi: 10.1158/2326-6066.CIR-14-0007. Epub 2014 Jun 17. Cancer Immunol Res. 2014. PMID: 24938283 Free PMC article.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Among authors: gilboa e. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
CD28 aptamers as powerful immune response modulators.
Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M. Pastor F, et al. Among authors: gilboa e. Mol Ther Nucleic Acids. 2013 Jun 11;2(6):e98. doi: 10.1038/mtna.2013.26. Mol Ther Nucleic Acids. 2013. PMID: 23756353 Free PMC article.
A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.
Gefen T, Castro I, Muharemagic D, Puplampu-Dove Y, Patel S, Gilboa E. Gefen T, et al. Among authors: gilboa e. Mol Ther. 2017 Oct 4;25(10):2280-2288. doi: 10.1016/j.ymthe.2017.06.023. Epub 2017 Aug 8. Mol Ther. 2017. PMID: 28800954 Free PMC article.
Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E, Berezhnoy A, Schrand B. Gilboa E, et al. Cancer Immunol Res. 2015 Nov;3(11):1195-200. doi: 10.1158/2326-6066.CIR-15-0194. Cancer Immunol Res. 2015. PMID: 26541880 Review.
Consensus nomenclature for CD8+ T cell phenotypes in cancer.
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Apetoh L, et al. Among authors: gilboa e. Oncoimmunology. 2015 Feb 25;4(4):e998538. doi: 10.1080/2162402X.2014.998538. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137416 Free PMC article.
Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.
Schrand B, Clark E, Levay A, Capote AR, Martinez O, Brenneman R, Castro I, Gilboa E. Schrand B, et al. Among authors: gilboa e. Nat Commun. 2018 Aug 22;9(1):3348. doi: 10.1038/s41467-018-05566-x. Nat Commun. 2018. PMID: 30135425 Free PMC article.
Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.
Puplampu-Dove Y, Gefen T, Rajagopalan A, Muheramagic D, Schrand B, Gilboa E. Puplampu-Dove Y, et al. Among authors: gilboa e. Oncoimmunology. 2018 Feb 15;7(4):e1349588. doi: 10.1080/2162402X.2017.1349588. eCollection 2018. Oncoimmunology. 2018. PMID: 29632714 Free PMC article.
Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.
Rajagopalan A, Berezhnoy A, Schrand B, Puplampu-Dove Y, Gilboa E. Rajagopalan A, et al. Among authors: gilboa e. Mol Ther. 2017 Jan 4;25(1):54-61. doi: 10.1016/j.ymthe.2016.10.021. Epub 2017 Jan 4. Mol Ther. 2017. PMID: 28129128 Free PMC article.
178 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback